IL6 and myeloid sarcoma: The differences reached statistical significance (retained after controlling for type I error) for IL-2 and IL-4 compared to MS, NIND and SC groups, for TNF-α compared to MS patients, for IFN-γ compared to MS and SC patients, and for IL-6 compared to MS patients.